45
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In December 2019, a cluster of acute respiratory illness caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) occurred in Wuhan, China. 1 , 2 Epidemiological and clinical characteristics, risk factors for mortality of patients infected with SARS‐CoV‐2, and risk factors in the susceptibility to SARS‐CoV‐2 included age and chronic disease have been reported. 3 , 4 , 5 , 6 However, the use of biological markers to predict the susceptibility to SARS‐CoV‐2 has not been well described. So far, only one study has reported that ABO blood groups were associated with the susceptibility to SARS‐CoV‐2· 7 In the present study, after eliminating other confounding risk factors (including age, gender and comorbidities), we further investigated and confirmed the association of ABO blood groups and risk of SARS‐CoV‐2 pneumonia in patients from the Central Hospital of Wuhan, as well as two hospitals in Wuhan, China. Patients diagnosed with SARS‐CoV‐2 who died or were discharged between February 1 and March 25, 2020, were included in this retrospective cohort study. The study was approved by the Ethics Committee of the Central Hospital of Wuhan, and the need for informed consent was waived. 8 Epidemiological information, clinical data, underlying comorbidities, CT images of lungs, laboratory findings and clinical outcomes were extracted from electronic medical records. The blood group distribution data of the other two hospitals (Wuhan Jinyintan Hospital and Renmin Hospital of Wuhan University) and healthy controls in Wuhan came from the paper published online. 7 Data were expressed as percentages (%). We used chi‐squared tests or Fisher's exact tests in order to compare the various groups. The ABO blood group in 265 patients infected with SARS‐CoV‐2 from the Central Hospital of Wuhan showed a distribution of 39·3 %, 25·3 %, 9·8 % and 25·7 % for A, B, AB and O, respectively (Table I). The proportion of blood group A in patients infected with SARS‐CoV‐2 was significantly higher than that in healthy controls (39·3 % vs. 32·3 %, P = 0·017), 7 while the proportion of blood group O in patients infected with SARS‐CoV‐2 was significantly lower than that in healthy controls (25·7 % vs. 33·8 %, P < 0·01). Table I The ABO blood group distribution in patients infected with SARS‐CoV‐2 and healthy controls in Wuhan. Blood Group A B AB O Controls (Wuhan Area, n = 3694), % 1188 (32·3 %) 920 (24·9 %) 336 (9·1 %) 1250 (33·8 %) Central Hospital of Wuhan (n = 265), % 104 (39·3) 67 (25·3) 26 (9·8) 68 (25·7) χ 2 5·645 0·019 0·152 7·447 P 0·017 0·891 0·696 < 0·01 Age distribution (n = 265), % Less than 40 years (n = 69) 24 (34·8) 17 (24·6) 8 (11·6) 20 (29·0) χ 2 0·213 0·003 0·509 0·714 P 0·644 0·959 0·476 0·398 Between 41–59 years (n = 79) 29 (36·7) 20 (25·3) 8 (10·1) 22 (27·9) χ 2 0·732 0·007 0·099 1·242 P 0·392 0·933 0·753 0·265 Over 60 years (n = 117) 51 (43·6) 30 (25·6) 10 (8·6) 26 (22·2) χ 2 6·752 0·033 0·041 6·871 P < 0·01 0·856 0·839 < 0·01 Gender distribution (n = 265), % Male (n = 113) 48 (42·5) 30 (26·6) 9 (8·0) 26 (23·0) χ 2 5·323 0·158 0·170 5·771 P 0·021 0·691 0·680 0·016 Female (n = 152) 56 (36·8) 37 (24·3) 17 (11·2) 42 (27·6) χ 2 1·462 0·025 0·764 2·521 P 0·227 0·875 0·382 0·112 Chronic disease, % Cerebrovascular disease (n = 55) 19 (34·6) 15 (27·3) 6 (10·9) 15 (27·3) χ 2 0·141 0·162 0·215 1·045 P 0·707 0·687 0·643 0·307 Coronary heart disease (n = 51) 18 (35·3) 14 (27·5) 7 (13·7) 12 (23·5) χ 2 0·226 0·174 1·296 2·393 P 0·634 0·676 0·255 0·122 Heart failure (n = 16) 2 (12·5) 6 (37·5) 1 (6·3) 7 (43·8) χ 2 2·826 1·349 0·000 0·699 P 0·093 0·245 1·000 0·403 Hypertension (n = 115) 48 (41·7) 26 (22·6) 10 (8·7) 31 (27·0) χ 2 4·668 0·315 0·022 2·367 P 0·031 0·575 0·883 0·124 Diabetes (n = 66) 26 (39·4) 19 (28·8) 4 (6·1) 17 (25·8) χ 2 1·552 0·522 0·726 1·895 P 0·213 0·470 0·394 0·169 Digestive disorder (n = 90) 33 (36·7) 26 (28·9) 7 (7·8) 23 (25·6) χ 2 0·816 0·744 0·185 2·700 P 0·366 0·389 0·667 0·100 COPD (n = 11) 4 (36·4) 4 (36·4) 1 (9·1) 2 (18·2) χ 2 0·089 0·769 0·000 0·604 P 0·766 0·380 1·000 0·437 Solid tumour (n = 27) 13 (48·2) 8 (29·6) 1 (3·7) 5 (18·5) χ 2 3·134 0·320 0·405 2·815 P 0·077 0·572 0·525 0·093 Chronic renal disease (n = 41) 15 (36·6) 12 (29·3) 2 (4·9) 12 (29·3) χ 2 0·364 0·708 0·439 0·379 P 0·546 0·400 0·508 0·538 Hepatitis (n = 7) 6 (85·7) 1 (14·3) 0 (0) 0 (0) χ 2 6·883 0·422 0·032 2·224 P < 0·01 0·516 0·858 0·136 Deaths (n = 57), % 20 (35·1) 15 (26·3) 8 (14·0) 14 (24·6) χ 2 0·220 0·060 1·644 2·162 P 0·639 0·807 0·200 0·141 COPD, chronic obstructive pulmonary disease. John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. We next investigated whether age, gender and chronic disease influence the ABO blood group distribution (Table I). The results showed that, among blood group A (43·6 % vs. 32·2 % in controls, P < 0·01) and blood group O (22·2 % vs. 33·8 % in controls, P < 0·01), patients over 60 years of age were consistent with all the above patients. Similarly, we also found that A (42·5 % vs. 32·2 %, P = 0·021) and O (23·0 % vs. 33·8 %, P = 0·016) distribution of blood groups in male patients was consistent with all the above patients. In all chronic diseases, we found that the proportion of hypertension (41·7 % vs. 32·2 %, P = 0·031) and hepatitis (85·7 % vs. 32·2 %, P < 0·01) in blood group A was much higher than that in the control group; however, there is currently no literature supporting that hypertension and hepatitis increase the risk of infection of SARS‐CoV‐2. In dead patients, we found no differences between blood types. Finally, we integrated the data of the three hospitals in Wuhan for analysis (Table II). 7 We still find that the proportion of blood group A in patients infected with SARS‐CoV‐2 was significantly higher than that in healthy controls (38·0 % vs. 32·2 %, P < 0·001), while the proportion of blood group O in SARS‐CoV‐2 infected patients was significantly lower than in healthy controls (25·7 % vs. 33·8 %, P < 0·001). The distribution ratio of blood type A and O between various ages and genders was almost consistent with the trend of all patients. Table II The ABO blood group distribution in patients infected with SARS‐CoV‐2 from three Wuhan hospitals. Blood Group A B AB O Controls (Wuhan Area, n = 3694), % 1188 (32·2) 920 (24·9) 336 (9·1) 1250 (33·8) Three Wuhan Hospitals (n = 2153), % 819 (38·0) 561 (26·1) 219 (10·2) 554 (25·7) χ 2 20·859 0·953 1·833 36·445 P <0·001 0·329 0·176 <0·001 Age distribution (n = 2153), % Less than 40 years (n = 342) 124 (36·3) 95 (27·8) 29 (8·5) 94 (27·5) χ 2 2·395 1·372 0·145 5·688 P 0·122 0·241 0·704 0·017 Between 41–59 years (n = 784) 304 (38·8) 196 (25·0) 79 (10·1) 205 (26·2) χ 2 12·739 0·003 0·740 17·439 P <0·001 0·956 0·390 <0·001 Over 60 years (n = 1027) 391 (38·1) 270 (26·3) 111 (10·8) 255 (24·8) χ 2 12·617 0·818 2·749 30·034 P <0·001 0·366 0·097 <0·001 Gender distribution (n = 2153), % Male (n = 1143) 451 (39·5) 305 (26·7) 110 (9·6) 277 (24·2) χ 2 20·749 1·461 0·291 37·271 P <0·001 0·227 0·590 <0·001 Female (n = 1010) 368 (36·4) 256 (25·4) 109 (10·8) 277 (27·4) χ 2 6·549 0·082 2·664 14·878 P 0·010 0·774 0·103 <0·001 Three Wuhan hospitals: the Central Hospital of Wuhan, Wuhan Jinyintan Hospital and Renmin Hospital of Wuhan University. John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. In this study, we demonstrated that blood group A patients were at higher risk of hospitalization following SARS‐CoV‐2 infection, while blood group O patients had lower risk, which suggested that the ABO blood type could be used as a biomarker to predict the risk of SARS‐CoV‐2 infection. Coincidentally, previous studies found that ABO blood type distribution also had significant differences in other viral infections. Chen et al. reported that blood group O individuals were less likely to become infected by SARS coronavirus, 9 Batool et al. found that blood group O might have some influence in protecting against blood‐transmitted infection, and people having blood group A were more prone to contract  hepatitis B  and HIV. 10 Jing et al. found that blood group B was associated with a lower risk of HBV infection. 11 Guillon et al. reported that the S protein/angiotensin‐converting enzyme 2‐dependent adhesion of these cells to an angiotensin‐converting enzyme 2 expressing cell line was specifically inhibited by human natural anti‐A antibodies, which might block the interaction between the virus and its receptor. 12 This could explain why blood group A is susceptible, while blood group O is not. However, there may be other factors that need further study. In summary, based on our research, and confirmed by reported data, people with blood group A had a significantly higher risk of SARS‐CoV‐2 infection, whereas blood group O had a significantly lower risk of SARS‐CoV‐2 infection. People with blood type A should strengthen protection to reduce the risk of infection; however, people with blood type O should not take the virus lightly, and must still take precautions to avoid increasing the risk of infection. The underlying molecular mechanism of our findings will need further study. Funding information This study was supported by the Health and Family Planning Commission of Wuhan City (WX18M02). Conflict of interest No reports. Authors' contribution Conceived and designed the experiments: J.L., M.Y. and A.D. Performed the experiments: J.L., X.W. and A.D. Analysed the data: J.L., X.W., J.C. and A.D. Wrote the paper: J.L. J.L. and X.W. contributed equally.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical Characteristics of Coronavirus Disease 2019 in China

          Abstract Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients. Methods We extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death. Results The median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission. Conclusions During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

            Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p<0·0001), and d-dimer greater than 1 μg/mL (18·42, 2·64–128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0–24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days. Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A Novel Coronavirus from Patients with Pneumonia in China, 2019

              Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
                Bookmark

                Author and article information

                Contributors
                dapyxb@163.com
                2217137592@qq.com
                Journal
                Br J Haematol
                Br. J. Haematol
                10.1111/(ISSN)1365-2141
                BJH
                British Journal of Haematology
                John Wiley and Sons Inc. (Hoboken )
                0007-1048
                1365-2141
                26 May 2020
                : 10.1111/bjh.16797
                Affiliations
                [ 1 ] Department of Pharmacy Key Laboratory for Molecular Diagnosis of Hubei Province The central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China
                [ 2 ] Department of Pain The central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China
                [ 3 ] Department of Information The central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China
                [ 4 ] Department of Plastic surgery Hospital Dean's Office The central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China
                Author notes
                [*] [* ] E‐mails: dapyxb@ 123456163.com (A. D.); 2217137592@ 123456qq.com (M. Y.)

                [†]

                Juyi Li and Xiufang Wang contributed equally.

                Author information
                https://orcid.org/0000-0002-5141-4655
                https://orcid.org/0000-0003-2119-7570
                https://orcid.org/0000-0002-2795-6884
                Article
                BJH16797
                10.1111/bjh.16797
                7267665
                32379894
                e6e0434c-4f79-4378-8c04-7ee894755ef7
                © 2020 British Society for Haematology and John Wiley & Sons Ltd

                This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

                History
                Page count
                Figures: 0, Tables: 2, Pages: 4, Words: 5792
                Funding
                Funded by: Health and Family Planning Commission of Wuhan City
                Award ID: WX18M02
                Categories
                Correspondence
                Correspondence
                Custom metadata
                2.0
                corrected-proof
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:03.06.2020

                Hematology
                abo blood groups,infection,markers,pneumonia,sars‐cov‐2
                Hematology
                abo blood groups, infection, markers, pneumonia, sars‐cov‐2

                Comments

                Comment on this article